Funded Biotechnology Startups in Basel
Basel-headquartered biotechnology rounds in this view span from 2020-04-22 (FoRx Therapeutics) through 2026-06-11 (ClearideBio Therapeutics).
Basel-headquartered biotechnology rounds in this view span from 2020-04-22 (FoRx Therapeutics) through 2026-06-11 (ClearideBio Therapeutics). The disclosed-size distribution is sharply top-heavy: the largest disclosed round is Noema Pharma’s $147M (2024-12-11), and it sits well above the next tier of large rounds such as Granite Bio’s $70M (2025-04-24) and Windward Bio’s $165M is the actual maximum with $165M (2026-05-04), dwarfs most others shown.
Timing also clusters: several sizable rounds land between late 2024 and 2025, including Noema Pharma ($147M, 2024-12-11), Allegria Therapeutics ($5M, 2025-12-11) and Aukera Therapeutics ($6M, 2025-12-11), plus Granite Bio ($70M, 2025-04-24). Stage labeling is incomplete in a measurable way: 2 entries are “undisclosed” (ClearideBio Therapeutics 2026-06-11; FimmCyte 2023-09-05) and 5 entries use “Series Unknown” (BioVersys 2024-09-11; FimmCyte 2023-09-05; Kinarus Therapeutics 2023-05-11; Bright Peak Therapeutics 2021-06-10; TargImmune Therapeutics 2021-07-19), while the list otherwise mixes Seed, Series A, Series B, Series C, debt, and post-IPO equity.
Most recent rounds
27 shownRelated listings
Frequently asked
What’s the largest disclosed round in Basel biotech here, and how does it compare to the rest of the disclosed amounts?
The largest disclosed amount is Windward Bio’s $165M on 2026-05-04. The next-largest disclosed values include Noema Pharma at $147M (2024-12-11) and Granite Bio at $70M (2025-04-24), with most other disclosed rounds falling far below that upper band (for example, $30M for Vector BioPharma on 2022-08-10 and $25M for T3 Pharmaceuticals on 2020-07-22).
Are there noticeable time clusters among the larger disclosed rounds in this 27-company snapshot?
Yes. The biggest concentrations appear in late 2024 through 2025, including Noema Pharma’s $147M (2024-12-11) and Windward Bio’s $165M (2026-05-04) with Granite Bio’s $70M (2025-04-24) in the same broader window. There’s also a same-day funding pattern in December 2025: Allegria Therapeutics ($5M, 2025-12-11) and Aukera Therapeutics ($6M, 2025-12-11).
Which entries are true outliers by disclosed amount, either extremely small or missing disclosed figures?
The smallest disclosed amount is $100K, appearing multiple times via debt/private-equity structures (FGen on 2021-12-12; MaxWell Biosystems on 2021-12-10; ten23 health on 2021-09-01). At the other end, the two “undisclosed” entries (ClearideBio Therapeutics 2026-06-11; FimmCyte 2023-09-05) limit comparability, but among disclosed rounds the top ($165M Windward Bio, 2026-05-04) is far above most others such as $10M FoRx Therapeutics (2020-04-22) and $6M Versameb (2020-07-15).
How incomplete are the round-type labels in this list (Series Unknown and undisclosed), and where do they sit in time?
Five entries are labeled “Series Unknown” (e.g., BioVersys $6M on 2024-09-11; Kinarus Therapeutics $2M on 2023-05-11; Bright Peak Therapeutics $107M on 2021-06-10), spanning 2021 through 2024. Two additional entries are explicitly “undisclosed” (ClearideBio Therapeutics on 2026-06-11; FimmCyte on 2023-09-05), located at the newest and mid-range parts of the timeline.
Which stages appear most often, and does stage align with higher disclosed amounts in this view?
Seed rounds recur across multiple years (e.g., Allegria Therapeutics $5M on 2025-12-11; Aukera Therapeutics $6M on 2025-12-11; KetoSwiss $800K on 2023-08-03; Engimmune Therapeutics $16M on 2022-05-03). In contrast, the largest disclosed amounts are concentrated in later-stage labels such as Series B (Windward Bio $165M on 2026-05-04; Noema Pharma $147M on 2024-12-11; Granite Bio $70M on 2025-04-24) and Series C (Monte Rosa Therapeutics $95M on 2021-03-12).
How far back do these most-recent entries extend, and which company anchors the oldest date here?
The oldest row in the 27 shown dates back to 2020-04-22 with FoRx Therapeutics, and the newest is 2026-06-11 with ClearideBio Therapeutics. That creates a roughly six-year span across the Basel biotech companies listed, with the most recent cluster leaning into 2024–2026 funding dates (including Noema Pharma in 2024 and Windward Bio in 2026).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.